Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Santosh Maharjan

Psychiatry Warsaw, IN Medical Doctor

NPI 1073751616 CMS profile 321594

850 N Harrison St, Warsaw, IN 46580

Open in the dashboard

General payments

$2,873

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Santosh Maharjan of Warsaw, IN is reported in the CMS Open Payments database as having received $2,873 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $312 14
2024 General $372 16
2023 General $642 32
2022 General $746 65
2021 General $341 36
2020 General $71 4
2019 General $389 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Santosh Maharjan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Santosh Maharjan were reported at $312. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Santosh Maharjan Psychiatry median Middle half National median
2019 $389 $184 $59–$605 $163
2020 $71 $119 $36–$372 $114
2021 $341 $143 $43–$576 $132
2022 $746 $153 $50–$590 $149
2023 $642 $170 $56–$651 $160
2024 $372 $179 $57–$673 $164
2025 $312 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $853 39 payments
  2. Lundbeck LLC $336 55 payments
  3. ITI, Inc. $295 13 payments
  4. AbbVie, Inc. $259 22 payments
  5. Alkermes, Inc. $233 11 payments
  6. Neurocrine Biosciences, Inc. $217 11 payments
  7. Indivior Inc. $165 10 payments
  8. Sunovion Pharmaceuticals Inc. $138 14 payments
  9. Teva Pharmaceuticals USA, Inc. $131 8 payments
  10. Axsome Therapeutics, Inc. $70 3 payments
  11. Other $176 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,873 195 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $590 61 payments
  2. ABILIFY ASIMTUFII $297 12 payments
  3. REXULTI $271 13 payments
  4. CAPLYTA $267 12 payments
  5. VRAYLAR $259 22 payments
  6. ARISTADA Cns $233 11 payments
  7. ARISTADA Cns $233 11 payments
  8. ARISTADA Cns $199 9 payments
  9. ARISTADA Cns $199 9 payments
  10. LYBALVI $185 9 payments
  11. Other $1,152 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,116

Median for Psychiatry: 574

Drug cost

$545,990

Median for Psychiatry: $27,624

Branded share of claims

21.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 107 $322,651
Abilify Maintena Aripiprazole Brand 34 $89,651
Aristada Aripiprazole Lauroxil Brand 14 $48,151
Rexulti Brexpiprazole Brand 19 $28,702
Trintellix Vortioxetine Hydrobromide Brand 33 $14,937
Clozapine Generic 35 $4,430
Paliperidone Er Paliperidone Brand 32 $3,698
Divalproex Sodium Er Divalproex Sodium Brand 71 $3,272
Divalproex Sodium Generic 43 $2,865
Haloperidol Decanoate Generic 44 $2,704

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$16,928

Medicare's payments for the services billed

Medicare patients

37

Average age 50

Services billed

289

18 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 57%
High blood pressure 51%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $145
$145 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
$56 19 —
Auvelity
  • Axsome Therapeutics, Inc. $46
$46 — —
CAPLYTA
  • ITI, Inc. $26
$26 — —
VRAYLAR
  • AbbVie, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record